Literature DB >> 17313456

Glycosylation improves the central effects of DAMGO.

John J Lowery1, Larisa Yeomans, Charles M Keyari, Peg Davis, Frank Porreca, Brian I Knapp, Jean M Bidlack, Edward J Bilsky, Robin Polt.   

Abstract

A series of mu-agonist DAMGO analogs were synthesized and pharmacologically characterized to test the 'biousian' hypothesis of membrane hopping. DAMGO was altered by incorporating moieties of increasing water solubility into the C-terminus via carboxamide and simple glycoside additions. The hydrophilic C-terminal moieties were varied from glycinol in DAMGO (1) to l-serine amide (2), l-serine amide beta-d-xyloside (3), l-serine amide beta-d-glucoside (4), and finally to l-serine amide beta-lactoside (5). Opioid binding and mouse tail-flick studies were performed. Antinociceptive potency (intravenous) increased, passing through a maximum (A(50) approximately 0.2 micromol/kg) for 2 and 3 as membrane affinity versus water solubility became optimal, and dropped off (A(50) approximately 1.0 micromol/kg) for 4 and 5 as water solubility dominated molecular behavior. Intravenous A(50) values were plotted versus hydrodynamic values (glucose units, g.u.) for the glycoside moieties, or the hydrophilic/hydrophobic Connolly surface areas (A(50) versus e(-Awater/Alipid)), and provided either a V-shaped or a U-shaped curve, as predicted by the 'biousian' hypothesis. The mu-selective receptor profile was maintained (K(i)'s = 0.66-1.3 nm) upon modifications at the C-terminus. The optimal 'degree of glycosylation' for the DAMGO peptide message appears to be between 1.25 and 1.75 g.u. (hydrodynamic g.u.), or 0.75 and 0.90 in terms of the surface-derived amphipathicity values.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17313456     DOI: 10.1111/j.1747-0285.2007.00462.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  17 in total

Review 1.  Opioid glycopeptide analgesics derived from endogenous enkephalins and endorphins.

Authors:  Yingxue Li; Mark R Lefever; Dhanasekaran Muthu; Jean M Bidlack; Edward J Bilsky; Robin Polt
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

2.  MILD AND SELECTIVE O-GLYCOSYLATIONS OF PRIMARY ALCOHOLS WITH THE THIOGLUCOSAMINIDE DERIVATIVE PROMOTED BY N-IODOSUCCINIMIDE AND HBF(4)-ADOSROBED ON SILICA GEL.

Authors:  Michio Kurosu; Kai Li
Journal:  Heterocycles       Date:  2009-05-12       Impact factor: 0.831

3.  Phosphorylation of enkephalins: NMR and CD studies in aqueous and membrane-mimicking environments.

Authors:  Larisa Yeomans; Dhanasekaran Muthu; John J Lowery; Heather N Martinez; Leif Abrell; Guanxin Lin; Kyle Strom; Brian I Knapp; Jean M Bidlack; Edward J Bilsky; Robin Polt
Journal:  Chem Biol Drug Des       Date:  2011-09-26       Impact factor: 2.817

4.  In vivo characterization of MMP-2200, a mixed δ/μ opioid agonist, in mice.

Authors:  John J Lowery; Tyler J Raymond; Denise Giuvelis; Jean M Bidlack; Robin Polt; Edward J Bilsky
Journal:  J Pharmacol Exp Ther       Date:  2010-11-30       Impact factor: 4.030

5.  Fluorescent peptide-PNA chimeras for imaging monoamine oxidase A mRNA in neuronal cells.

Authors:  Dalip Sethi; Chang-Po Chen; Rui-Yan Jing; Mathew L Thakur; Eric Wickstrom
Journal:  Bioconjug Chem       Date:  2012-01-25       Impact factor: 4.774

6.  Effects of the novel glycopeptide opioid agonist MMP-2200 in preclinical models of Parkinson's disease.

Authors:  Xu Yue; Torsten Falk; Leslie A Zuniga; Lajos Szabò; Frank Porreca; Robin Polt; Scott J Sherman
Journal:  Brain Res       Date:  2011-07-23       Impact factor: 3.252

7.  A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction.

Authors:  Meredith Hay; Robin Polt; Michael L Heien; Todd W Vanderah; Tally M Largent-Milnes; Kathleen Rodgers; Torsten Falk; Mitchell J Bartlett; Kristian P Doyle; John P Konhilas
Journal:  J Pharmacol Exp Ther       Date:  2019-02-01       Impact factor: 4.030

8.  CNS penetration of the opioid glycopeptide MMP-2200: a microdialysis study.

Authors:  Omar S Mabrouk; Torsten Falk; Scott J Sherman; Robert T Kennedy; Robin Polt
Journal:  Neurosci Lett       Date:  2012-11-02       Impact factor: 3.046

9.  Behavioral pharmacology of the mu/delta opioid glycopeptide MMP2200 in rhesus monkeys.

Authors:  Gail Pereira Do Carmo; Robin Polt; Edward J Bilsky; Kenner C Rice; S Stevens Negus
Journal:  J Pharmacol Exp Ther       Date:  2008-05-29       Impact factor: 4.030

Review 10.  Glycopeptide drugs: A pharmacological dimension between "Small Molecules" and "Biologics".

Authors:  Christopher R Apostol; Meredith Hay; Robin Polt
Journal:  Peptides       Date:  2020-07-13       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.